Global GLP-1 Combination and Multi-agonist Drugs Supply, Demand and Key Producers, 2026-2032
The global GLP-1 Combination and Multi-agonist Drugs market size is expected to reach $ 61694 million by 2032, rising at a market growth of 17.1% CAGR during the forecast period (2026-2032).
GLP-1 combination and multi-agonist drugs are innovative medicines built around the GLP-1 pathway while also engaging GIP, glucagon, amylin or other metabolic targets to improve body weight, glucose control, fatty liver disease and cardiometabolic risk through synergistic mechanisms. The category includes dual agonists, tri-agonists, fixed-dose combinations and combination candidates, with evaluation focused on greater weight reduction, broader metabolic benefit, safety, dosing convenience and long-term adherence. In 2025, global GLP-1 Combination and Multi-agonist Drugs production reached approximately 320 million unit.The average gross profit margin of this product is 80%.
GLP-1 combination and multi-agonist drugs are among the most active innovation areas in obesity and metabolic disease. Dual- and tri-target mechanisms may further improve weight-loss efficacy beyond traditional GLP-1 therapy and expand use into diabetes, MASH and broader cardiometabolic risk management.
Industrial competition is concentrated among large global pharmaceutical companies and selected innovative biotechnology firms. Approved dual agonists have accelerated market education and physician adoption, while late-stage tri-agonists, GLP-1/glucagon dual agonists and amylin combinations may drive the next wave of differentiation.
Growth is influenced by clinical trial outcomes, long-term safety, capacity scale-up, drug pricing and payer coverage. Future market focus will shift toward the upper limit of efficacy, muscle-mass preservation, post-treatment weight management, liver metabolic improvement and integrated chronic disease care.
This report studies the global GLP-1 Combination and Multi-agonist Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for GLP-1 Combination and Multi-agonist Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Combination and Multi-agonist Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global GLP-1 Combination and Multi-agonist Drugs total production and demand, 2021-2032, (K Units)
Global GLP-1 Combination and Multi-agonist Drugs total production value, 2021-2032, (USD Million)
Global GLP-1 Combination and Multi-agonist Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global GLP-1 Combination and Multi-agonist Drugs consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: GLP-1 Combination and Multi-agonist Drugs domestic production, consumption, key domestic manufacturers and share
Global GLP-1 Combination and Multi-agonist Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global GLP-1 Combination and Multi-agonist Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global GLP-1 Combination and Multi-agonist Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global GLP-1 Combination and Multi-agonist Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, GSK, Hansoh, Huiren Bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Combination and Multi-agonist Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global GLP-1 Combination and Multi-agonist Drugs Market, By Region:
1. How big is the global GLP-1 Combination and Multi-agonist Drugs market?
2. What is the demand of the global GLP-1 Combination and Multi-agonist Drugs market?
3. What is the year over year growth of the global GLP-1 Combination and Multi-agonist Drugs market?
4. What is the production and production value of the global GLP-1 Combination and Multi-agonist Drugs market?
5. Who are the key producers in the global GLP-1 Combination and Multi-agonist Drugs market?
6. What are the growth factors driving the market demand?
GLP-1 combination and multi-agonist drugs are innovative medicines built around the GLP-1 pathway while also engaging GIP, glucagon, amylin or other metabolic targets to improve body weight, glucose control, fatty liver disease and cardiometabolic risk through synergistic mechanisms. The category includes dual agonists, tri-agonists, fixed-dose combinations and combination candidates, with evaluation focused on greater weight reduction, broader metabolic benefit, safety, dosing convenience and long-term adherence. In 2025, global GLP-1 Combination and Multi-agonist Drugs production reached approximately 320 million unit.The average gross profit margin of this product is 80%.
GLP-1 combination and multi-agonist drugs are among the most active innovation areas in obesity and metabolic disease. Dual- and tri-target mechanisms may further improve weight-loss efficacy beyond traditional GLP-1 therapy and expand use into diabetes, MASH and broader cardiometabolic risk management.
Industrial competition is concentrated among large global pharmaceutical companies and selected innovative biotechnology firms. Approved dual agonists have accelerated market education and physician adoption, while late-stage tri-agonists, GLP-1/glucagon dual agonists and amylin combinations may drive the next wave of differentiation.
Growth is influenced by clinical trial outcomes, long-term safety, capacity scale-up, drug pricing and payer coverage. Future market focus will shift toward the upper limit of efficacy, muscle-mass preservation, post-treatment weight management, liver metabolic improvement and integrated chronic disease care.
This report studies the global GLP-1 Combination and Multi-agonist Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for GLP-1 Combination and Multi-agonist Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Combination and Multi-agonist Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global GLP-1 Combination and Multi-agonist Drugs total production and demand, 2021-2032, (K Units)
Global GLP-1 Combination and Multi-agonist Drugs total production value, 2021-2032, (USD Million)
Global GLP-1 Combination and Multi-agonist Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global GLP-1 Combination and Multi-agonist Drugs consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: GLP-1 Combination and Multi-agonist Drugs domestic production, consumption, key domestic manufacturers and share
Global GLP-1 Combination and Multi-agonist Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global GLP-1 Combination and Multi-agonist Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global GLP-1 Combination and Multi-agonist Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global GLP-1 Combination and Multi-agonist Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, GSK, Hansoh, Huiren Bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Combination and Multi-agonist Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global GLP-1 Combination and Multi-agonist Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- GIP/GLP-1 Dual Agonist
- GLP-1/Glucagon Dual Agonist
- Amylin/GLP-1 Combination
- GIP/GLP-1/Glucagon Tri-agonist
- GLP-1 Plus Small Molecule
- Other
- Obesity
- Type 2 Diabetes
- MASH
- Cardiometabolic Disease
- Other
- Peptide Injection
- Long-acting Injection
- Oral Candidate
- Combination Kit
- Other
- Obesity Clinics
- Endocrinology Departments
- Metabolic Disease Centers
- Clinical Trial Sites
- Hospital Pharmacies
- Retail Pharmacies
- Other
- Eli Lilly
- Novo Nordisk
- Boehringer Ingelheim
- AstraZeneca
- Sanofi
- GSK
- Hansoh
- Huiren Bio
1. How big is the global GLP-1 Combination and Multi-agonist Drugs market?
2. What is the demand of the global GLP-1 Combination and Multi-agonist Drugs market?
3. What is the year over year growth of the global GLP-1 Combination and Multi-agonist Drugs market?
4. What is the production and production value of the global GLP-1 Combination and Multi-agonist Drugs market?
5. Who are the key producers in the global GLP-1 Combination and Multi-agonist Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 GLP-1 Combination and Multi-agonist Drugs Introduction
1.2 World GLP-1 Combination and Multi-agonist Drugs Supply & Forecast
1.2.1 World GLP-1 Combination and Multi-agonist Drugs Production Value (2021 & 2025 & 2032)
1.2.2 World GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.2.3 World GLP-1 Combination and Multi-agonist Drugs Pricing Trends (2021-2032)
1.3 World GLP-1 Combination and Multi-agonist Drugs Production by Region (Based on Production Site)
1.3.1 World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2021-2032)
1.3.2 World GLP-1 Combination and Multi-agonist Drugs Production by Region (2021-2032)
1.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2021-2032)
1.3.4 North America GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.5 Europe GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.6 China GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.7 Japan GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.8 India GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 GLP-1 Combination and Multi-agonist Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 GLP-1 Combination and Multi-agonist Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World GLP-1 Combination and Multi-agonist Drugs Demand (2021-2032)
2.2 World GLP-1 Combination and Multi-agonist Drugs Consumption by Region
2.2.1 World GLP-1 Combination and Multi-agonist Drugs Consumption by Region (2021-2026)
2.2.2 World GLP-1 Combination and Multi-agonist Drugs Consumption Forecast by Region (2027-2032)
2.3 United States GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.4 China GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.5 Europe GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.6 Japan GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.7 South Korea GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.8 ASEAN GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.9 India GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World GLP-1 Combination and Multi-agonist Drugs Production Value by Manufacturer (2021-2026)
3.2 World GLP-1 Combination and Multi-agonist Drugs Production by Manufacturer (2021-2026)
3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Manufacturer (2021-2026)
3.4 GLP-1 Combination and Multi-agonist Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global GLP-1 Combination and Multi-agonist Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for GLP-1 Combination and Multi-agonist Drugs in 2025
3.5.3 Global Concentration Ratios (CR8) for GLP-1 Combination and Multi-agonist Drugs in 2025
3.6 GLP-1 Combination and Multi-agonist Drugs Market: Overall Company Footprint Analysis
3.6.1 GLP-1 Combination and Multi-agonist Drugs Market: Region Footprint
3.6.2 GLP-1 Combination and Multi-agonist Drugs Market: Company Product Type Footprint
3.6.3 GLP-1 Combination and Multi-agonist Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Comparison
4.1.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Comparison
4.2.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Comparison
4.3.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based GLP-1 Combination and Multi-agonist Drugs Manufacturers and Market Share, 2021-2026
4.4.1 United States Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value (2021-2026)
4.4.3 United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026)
4.5 China Based GLP-1 Combination and Multi-agonist Drugs Manufacturers and Market Share
4.5.1 China Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value (2021-2026)
4.5.3 China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026)
4.6 Rest of World Based GLP-1 Combination and Multi-agonist Drugs Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 GIP/GLP-1 Dual Agonist
5.2.2 GLP-1/Glucagon Dual Agonist
5.2.3 Amylin/GLP-1 Combination
5.2.4 GIP/GLP-1/Glucagon Tri-agonist
5.2.5 GLP-1 Plus Small Molecule
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Type (2021-2032)
5.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Type (2021-2032)
5.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY INDICATION
6.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Indication: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Indication
6.2.1 Obesity
6.2.2 Type 2 Diabetes
6.2.3 MASH
6.2.4 Cardiometabolic Disease
6.2.5 Other
6.3 Market Segment by Indication
6.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Indication (2021-2032)
6.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication (2021-2032)
6.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2021-2032)
7 MARKET ANALYSIS BY DOSAGE FORM
7.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dosage Form
7.2.1 Peptide Injection
7.2.2 Long-acting Injection
7.2.3 Oral Candidate
7.2.4 Combination Kit
7.2.5 Other
7.3 Market Segment by Dosage Form
7.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Dosage Form (2021-2032)
7.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form (2021-2032)
7.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Obesity Clinics
8.2.2 Endocrinology Departments
8.2.3 Metabolic Disease Centers
8.2.4 Clinical Trial Sites
8.2.5 Hospital Pharmacies
8.2.6 Retail Pharmacies
8.2.7 Other
8.3 Market Segment by Application
8.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Application (2021-2032)
8.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Application (2021-2032)
8.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Eli Lilly
9.1.1 Eli Lilly Details
9.1.2 Eli Lilly Major Business
9.1.3 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product and Services
9.1.4 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Eli Lilly Recent Developments/Updates
9.1.6 Eli Lilly Competitive Strengths & Weaknesses
9.2 Novo Nordisk
9.2.1 Novo Nordisk Details
9.2.2 Novo Nordisk Major Business
9.2.3 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product and Services
9.2.4 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novo Nordisk Recent Developments/Updates
9.2.6 Novo Nordisk Competitive Strengths & Weaknesses
9.3 Boehringer Ingelheim
9.3.1 Boehringer Ingelheim Details
9.3.2 Boehringer Ingelheim Major Business
9.3.3 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product and Services
9.3.4 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Boehringer Ingelheim Recent Developments/Updates
9.3.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product and Services
9.4.4 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Sanofi
9.5.1 Sanofi Details
9.5.2 Sanofi Major Business
9.5.3 Sanofi GLP-1 Combination and Multi-agonist Drugs Product and Services
9.5.4 Sanofi GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Sanofi Recent Developments/Updates
9.5.6 Sanofi Competitive Strengths & Weaknesses
9.6 GSK
9.6.1 GSK Details
9.6.2 GSK Major Business
9.6.3 GSK GLP-1 Combination and Multi-agonist Drugs Product and Services
9.6.4 GSK GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 GSK Recent Developments/Updates
9.6.6 GSK Competitive Strengths & Weaknesses
9.7 Hansoh
9.7.1 Hansoh Details
9.7.2 Hansoh Major Business
9.7.3 Hansoh GLP-1 Combination and Multi-agonist Drugs Product and Services
9.7.4 Hansoh GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Hansoh Recent Developments/Updates
9.7.6 Hansoh Competitive Strengths & Weaknesses
9.8 Huiren Bio
9.8.1 Huiren Bio Details
9.8.2 Huiren Bio Major Business
9.8.3 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product and Services
9.8.4 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Huiren Bio Recent Developments/Updates
9.8.6 Huiren Bio Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 GLP-1 Combination and Multi-agonist Drugs Industry Chain
10.2 GLP-1 Combination and Multi-agonist Drugs Upstream Analysis
10.2.1 GLP-1 Combination and Multi-agonist Drugs Core Raw Materials
10.2.2 Main Manufacturers of GLP-1 Combination and Multi-agonist Drugs Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 GLP-1 Combination and Multi-agonist Drugs Production Mode
10.6 GLP-1 Combination and Multi-agonist Drugs Procurement Model
10.7 GLP-1 Combination and Multi-agonist Drugs Industry Sales Model and Sales Channels
10.7.1 GLP-1 Combination and Multi-agonist Drugs Sales Model
10.7.2 GLP-1 Combination and Multi-agonist Drugs Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 GLP-1 Combination and Multi-agonist Drugs Introduction
1.2 World GLP-1 Combination and Multi-agonist Drugs Supply & Forecast
1.2.1 World GLP-1 Combination and Multi-agonist Drugs Production Value (2021 & 2025 & 2032)
1.2.2 World GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.2.3 World GLP-1 Combination and Multi-agonist Drugs Pricing Trends (2021-2032)
1.3 World GLP-1 Combination and Multi-agonist Drugs Production by Region (Based on Production Site)
1.3.1 World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2021-2032)
1.3.2 World GLP-1 Combination and Multi-agonist Drugs Production by Region (2021-2032)
1.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2021-2032)
1.3.4 North America GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.5 Europe GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.6 China GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.7 Japan GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.3.8 India GLP-1 Combination and Multi-agonist Drugs Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 GLP-1 Combination and Multi-agonist Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 GLP-1 Combination and Multi-agonist Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World GLP-1 Combination and Multi-agonist Drugs Demand (2021-2032)
2.2 World GLP-1 Combination and Multi-agonist Drugs Consumption by Region
2.2.1 World GLP-1 Combination and Multi-agonist Drugs Consumption by Region (2021-2026)
2.2.2 World GLP-1 Combination and Multi-agonist Drugs Consumption Forecast by Region (2027-2032)
2.3 United States GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.4 China GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.5 Europe GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.6 Japan GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.7 South Korea GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.8 ASEAN GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
2.9 India GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World GLP-1 Combination and Multi-agonist Drugs Production Value by Manufacturer (2021-2026)
3.2 World GLP-1 Combination and Multi-agonist Drugs Production by Manufacturer (2021-2026)
3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Manufacturer (2021-2026)
3.4 GLP-1 Combination and Multi-agonist Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global GLP-1 Combination and Multi-agonist Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for GLP-1 Combination and Multi-agonist Drugs in 2025
3.5.3 Global Concentration Ratios (CR8) for GLP-1 Combination and Multi-agonist Drugs in 2025
3.6 GLP-1 Combination and Multi-agonist Drugs Market: Overall Company Footprint Analysis
3.6.1 GLP-1 Combination and Multi-agonist Drugs Market: Region Footprint
3.6.2 GLP-1 Combination and Multi-agonist Drugs Market: Company Product Type Footprint
3.6.3 GLP-1 Combination and Multi-agonist Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Comparison
4.1.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Comparison
4.2.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Comparison
4.3.1 United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based GLP-1 Combination and Multi-agonist Drugs Manufacturers and Market Share, 2021-2026
4.4.1 United States Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value (2021-2026)
4.4.3 United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026)
4.5 China Based GLP-1 Combination and Multi-agonist Drugs Manufacturers and Market Share
4.5.1 China Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value (2021-2026)
4.5.3 China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026)
4.6 Rest of World Based GLP-1 Combination and Multi-agonist Drugs Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 GIP/GLP-1 Dual Agonist
5.2.2 GLP-1/Glucagon Dual Agonist
5.2.3 Amylin/GLP-1 Combination
5.2.4 GIP/GLP-1/Glucagon Tri-agonist
5.2.5 GLP-1 Plus Small Molecule
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Type (2021-2032)
5.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Type (2021-2032)
5.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY INDICATION
6.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Indication: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Indication
6.2.1 Obesity
6.2.2 Type 2 Diabetes
6.2.3 MASH
6.2.4 Cardiometabolic Disease
6.2.5 Other
6.3 Market Segment by Indication
6.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Indication (2021-2032)
6.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication (2021-2032)
6.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2021-2032)
7 MARKET ANALYSIS BY DOSAGE FORM
7.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dosage Form
7.2.1 Peptide Injection
7.2.2 Long-acting Injection
7.2.3 Oral Candidate
7.2.4 Combination Kit
7.2.5 Other
7.3 Market Segment by Dosage Form
7.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Dosage Form (2021-2032)
7.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form (2021-2032)
7.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World GLP-1 Combination and Multi-agonist Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Obesity Clinics
8.2.2 Endocrinology Departments
8.2.3 Metabolic Disease Centers
8.2.4 Clinical Trial Sites
8.2.5 Hospital Pharmacies
8.2.6 Retail Pharmacies
8.2.7 Other
8.3 Market Segment by Application
8.3.1 World GLP-1 Combination and Multi-agonist Drugs Production by Application (2021-2032)
8.3.2 World GLP-1 Combination and Multi-agonist Drugs Production Value by Application (2021-2032)
8.3.3 World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Eli Lilly
9.1.1 Eli Lilly Details
9.1.2 Eli Lilly Major Business
9.1.3 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product and Services
9.1.4 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Eli Lilly Recent Developments/Updates
9.1.6 Eli Lilly Competitive Strengths & Weaknesses
9.2 Novo Nordisk
9.2.1 Novo Nordisk Details
9.2.2 Novo Nordisk Major Business
9.2.3 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product and Services
9.2.4 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novo Nordisk Recent Developments/Updates
9.2.6 Novo Nordisk Competitive Strengths & Weaknesses
9.3 Boehringer Ingelheim
9.3.1 Boehringer Ingelheim Details
9.3.2 Boehringer Ingelheim Major Business
9.3.3 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product and Services
9.3.4 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Boehringer Ingelheim Recent Developments/Updates
9.3.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product and Services
9.4.4 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Sanofi
9.5.1 Sanofi Details
9.5.2 Sanofi Major Business
9.5.3 Sanofi GLP-1 Combination and Multi-agonist Drugs Product and Services
9.5.4 Sanofi GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Sanofi Recent Developments/Updates
9.5.6 Sanofi Competitive Strengths & Weaknesses
9.6 GSK
9.6.1 GSK Details
9.6.2 GSK Major Business
9.6.3 GSK GLP-1 Combination and Multi-agonist Drugs Product and Services
9.6.4 GSK GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 GSK Recent Developments/Updates
9.6.6 GSK Competitive Strengths & Weaknesses
9.7 Hansoh
9.7.1 Hansoh Details
9.7.2 Hansoh Major Business
9.7.3 Hansoh GLP-1 Combination and Multi-agonist Drugs Product and Services
9.7.4 Hansoh GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Hansoh Recent Developments/Updates
9.7.6 Hansoh Competitive Strengths & Weaknesses
9.8 Huiren Bio
9.8.1 Huiren Bio Details
9.8.2 Huiren Bio Major Business
9.8.3 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product and Services
9.8.4 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Huiren Bio Recent Developments/Updates
9.8.6 Huiren Bio Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 GLP-1 Combination and Multi-agonist Drugs Industry Chain
10.2 GLP-1 Combination and Multi-agonist Drugs Upstream Analysis
10.2.1 GLP-1 Combination and Multi-agonist Drugs Core Raw Materials
10.2.2 Main Manufacturers of GLP-1 Combination and Multi-agonist Drugs Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 GLP-1 Combination and Multi-agonist Drugs Production Mode
10.6 GLP-1 Combination and Multi-agonist Drugs Procurement Model
10.7 GLP-1 Combination and Multi-agonist Drugs Industry Sales Model and Sales Channels
10.7.1 GLP-1 Combination and Multi-agonist Drugs Sales Model
10.7.2 GLP-1 Combination and Multi-agonist Drugs Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2021-2026) & (USD Million)
Table 3. World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2027-2032) & (USD Million)
Table 4. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Region (2021-2026)
Table 5. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Region (2027-2032)
Table 6. World GLP-1 Combination and Multi-agonist Drugs Production by Region (2021-2026) & (K Units)
Table 7. World GLP-1 Combination and Multi-agonist Drugs Production by Region (2027-2032) & (K Units)
Table 8. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Region (2021-2026)
Table 9. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Region (2027-2032)
Table 10. World GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2027-2032) & (US$/Unit)
Table 12. GLP-1 Combination and Multi-agonist Drugs Major Market Trends
Table 13. World GLP-1 Combination and Multi-agonist Drugs Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World GLP-1 Combination and Multi-agonist Drugs Consumption by Region (2021-2026) & (K Units)
Table 15. World GLP-1 Combination and Multi-agonist Drugs Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World GLP-1 Combination and Multi-agonist Drugs Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key GLP-1 Combination and Multi-agonist Drugs Producers in 2025
Table 18. World GLP-1 Combination and Multi-agonist Drugs Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key GLP-1 Combination and Multi-agonist Drugs Producers in 2025
Table 20. World GLP-1 Combination and Multi-agonist Drugs Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global GLP-1 Combination and Multi-agonist Drugs Company Evaluation Quadrant
Table 22. World GLP-1 Combination and Multi-agonist Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and GLP-1 Combination and Multi-agonist Drugs Production Site of Key Manufacturer
Table 24. GLP-1 Combination and Multi-agonist Drugs Market: Company Product Type Footprint
Table 25. GLP-1 Combination and Multi-agonist Drugs Market: Company Product Application Footprint
Table 26. GLP-1 Combination and Multi-agonist Drugs Competitive Factors
Table 27. GLP-1 Combination and Multi-agonist Drugs New Entrant and Capacity Expansion Plans
Table 28. GLP-1 Combination and Multi-agonist Drugs Mergers & Acquisitions Activity
Table 29. United States VS China GLP-1 Combination and Multi-agonist Drugs Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China GLP-1 Combination and Multi-agonist Drugs Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China GLP-1 Combination and Multi-agonist Drugs Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share (2021-2026)
Table 37. China Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share (2021-2026)
Table 42. Rest of World Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share (2021-2026)
Table 47. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World GLP-1 Combination and Multi-agonist Drugs Production by Type (2021-2026) & (K Units)
Table 49. World GLP-1 Combination and Multi-agonist Drugs Production by Type (2027-2032) & (K Units)
Table 50. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type (2021-2026) & (USD Million)
Table 51. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type (2027-2032) & (USD Million)
Table 52. World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 55. World GLP-1 Combination and Multi-agonist Drugs Production by Indication (2021-2026) & (K Units)
Table 56. World GLP-1 Combination and Multi-agonist Drugs Production by Indication (2027-2032) & (K Units)
Table 57. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication (2021-2026) & (USD Million)
Table 58. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication (2027-2032) & (USD Million)
Table 59. World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2021-2026) & (US$/Unit)
Table 60. World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2027-2032) & (US$/Unit)
Table 61. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 62. World GLP-1 Combination and Multi-agonist Drugs Production by Dosage Form (2021-2026) & (K Units)
Table 63. World GLP-1 Combination and Multi-agonist Drugs Production by Dosage Form (2027-2032) & (K Units)
Table 64. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form (2021-2026) & (USD Million)
Table 65. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form (2027-2032) & (USD Million)
Table 66. World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2021-2026) & (US$/Unit)
Table 67. World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2027-2032) & (US$/Unit)
Table 68. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World GLP-1 Combination and Multi-agonist Drugs Production by Application (2021-2026) & (K Units)
Table 70. World GLP-1 Combination and Multi-agonist Drugs Production by Application (2027-2032) & (K Units)
Table 71. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application (2021-2026) & (USD Million)
Table 72. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application (2027-2032) & (USD Million)
Table 73. World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 76. Eli Lilly Major Business
Table 77. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 78. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Eli Lilly Competitive Strengths & Weaknesses
Table 81. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 82. Novo Nordisk Major Business
Table 83. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 84. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novo Nordisk Recent Developments/Updates
Table 86. Novo Nordisk Competitive Strengths & Weaknesses
Table 87. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 88. Boehringer Ingelheim Major Business
Table 89. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 90. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Boehringer Ingelheim Recent Developments/Updates
Table 92. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 93. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 94. AstraZeneca Major Business
Table 95. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 96. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. AstraZeneca Recent Developments/Updates
Table 98. AstraZeneca Competitive Strengths & Weaknesses
Table 99. Sanofi Basic Information, Manufacturing Base and Competitors
Table 100. Sanofi Major Business
Table 101. Sanofi GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 102. Sanofi GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Sanofi Recent Developments/Updates
Table 104. Sanofi Competitive Strengths & Weaknesses
Table 105. GSK Basic Information, Manufacturing Base and Competitors
Table 106. GSK Major Business
Table 107. GSK GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 108. GSK GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. GSK Recent Developments/Updates
Table 110. GSK Competitive Strengths & Weaknesses
Table 111. Hansoh Basic Information, Manufacturing Base and Competitors
Table 112. Hansoh Major Business
Table 113. Hansoh GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 114. Hansoh GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Hansoh Recent Developments/Updates
Table 116. Hansoh Competitive Strengths & Weaknesses
Table 117. Huiren Bio Basic Information, Manufacturing Base and Competitors
Table 118. Huiren Bio Major Business
Table 119. Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 120. Huiren Bio GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Huiren Bio Recent Developments/Updates
Table 122. Huiren Bio Competitive Strengths & Weaknesses
Table 123. Global Key Players of GLP-1 Combination and Multi-agonist Drugs Upstream (Raw Materials)
Table 124. Global GLP-1 Combination and Multi-agonist Drugs Typical Customers
Table 125. GLP-1 Combination and Multi-agonist Drugs Typical Distributors
Table 1. World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2021-2026) & (USD Million)
Table 3. World GLP-1 Combination and Multi-agonist Drugs Production Value by Region (2027-2032) & (USD Million)
Table 4. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Region (2021-2026)
Table 5. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Region (2027-2032)
Table 6. World GLP-1 Combination and Multi-agonist Drugs Production by Region (2021-2026) & (K Units)
Table 7. World GLP-1 Combination and Multi-agonist Drugs Production by Region (2027-2032) & (K Units)
Table 8. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Region (2021-2026)
Table 9. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Region (2027-2032)
Table 10. World GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World GLP-1 Combination and Multi-agonist Drugs Average Price by Region (2027-2032) & (US$/Unit)
Table 12. GLP-1 Combination and Multi-agonist Drugs Major Market Trends
Table 13. World GLP-1 Combination and Multi-agonist Drugs Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World GLP-1 Combination and Multi-agonist Drugs Consumption by Region (2021-2026) & (K Units)
Table 15. World GLP-1 Combination and Multi-agonist Drugs Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World GLP-1 Combination and Multi-agonist Drugs Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key GLP-1 Combination and Multi-agonist Drugs Producers in 2025
Table 18. World GLP-1 Combination and Multi-agonist Drugs Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key GLP-1 Combination and Multi-agonist Drugs Producers in 2025
Table 20. World GLP-1 Combination and Multi-agonist Drugs Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global GLP-1 Combination and Multi-agonist Drugs Company Evaluation Quadrant
Table 22. World GLP-1 Combination and Multi-agonist Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and GLP-1 Combination and Multi-agonist Drugs Production Site of Key Manufacturer
Table 24. GLP-1 Combination and Multi-agonist Drugs Market: Company Product Type Footprint
Table 25. GLP-1 Combination and Multi-agonist Drugs Market: Company Product Application Footprint
Table 26. GLP-1 Combination and Multi-agonist Drugs Competitive Factors
Table 27. GLP-1 Combination and Multi-agonist Drugs New Entrant and Capacity Expansion Plans
Table 28. GLP-1 Combination and Multi-agonist Drugs Mergers & Acquisitions Activity
Table 29. United States VS China GLP-1 Combination and Multi-agonist Drugs Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China GLP-1 Combination and Multi-agonist Drugs Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China GLP-1 Combination and Multi-agonist Drugs Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share (2021-2026)
Table 37. China Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share (2021-2026)
Table 42. Rest of World Based GLP-1 Combination and Multi-agonist Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share (2021-2026)
Table 47. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World GLP-1 Combination and Multi-agonist Drugs Production by Type (2021-2026) & (K Units)
Table 49. World GLP-1 Combination and Multi-agonist Drugs Production by Type (2027-2032) & (K Units)
Table 50. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type (2021-2026) & (USD Million)
Table 51. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type (2027-2032) & (USD Million)
Table 52. World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 55. World GLP-1 Combination and Multi-agonist Drugs Production by Indication (2021-2026) & (K Units)
Table 56. World GLP-1 Combination and Multi-agonist Drugs Production by Indication (2027-2032) & (K Units)
Table 57. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication (2021-2026) & (USD Million)
Table 58. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication (2027-2032) & (USD Million)
Table 59. World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2021-2026) & (US$/Unit)
Table 60. World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2027-2032) & (US$/Unit)
Table 61. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 62. World GLP-1 Combination and Multi-agonist Drugs Production by Dosage Form (2021-2026) & (K Units)
Table 63. World GLP-1 Combination and Multi-agonist Drugs Production by Dosage Form (2027-2032) & (K Units)
Table 64. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form (2021-2026) & (USD Million)
Table 65. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form (2027-2032) & (USD Million)
Table 66. World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2021-2026) & (US$/Unit)
Table 67. World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2027-2032) & (US$/Unit)
Table 68. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World GLP-1 Combination and Multi-agonist Drugs Production by Application (2021-2026) & (K Units)
Table 70. World GLP-1 Combination and Multi-agonist Drugs Production by Application (2027-2032) & (K Units)
Table 71. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application (2021-2026) & (USD Million)
Table 72. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application (2027-2032) & (USD Million)
Table 73. World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 76. Eli Lilly Major Business
Table 77. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 78. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Eli Lilly Competitive Strengths & Weaknesses
Table 81. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 82. Novo Nordisk Major Business
Table 83. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 84. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novo Nordisk Recent Developments/Updates
Table 86. Novo Nordisk Competitive Strengths & Weaknesses
Table 87. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 88. Boehringer Ingelheim Major Business
Table 89. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 90. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Boehringer Ingelheim Recent Developments/Updates
Table 92. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 93. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 94. AstraZeneca Major Business
Table 95. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 96. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. AstraZeneca Recent Developments/Updates
Table 98. AstraZeneca Competitive Strengths & Weaknesses
Table 99. Sanofi Basic Information, Manufacturing Base and Competitors
Table 100. Sanofi Major Business
Table 101. Sanofi GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 102. Sanofi GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Sanofi Recent Developments/Updates
Table 104. Sanofi Competitive Strengths & Weaknesses
Table 105. GSK Basic Information, Manufacturing Base and Competitors
Table 106. GSK Major Business
Table 107. GSK GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 108. GSK GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. GSK Recent Developments/Updates
Table 110. GSK Competitive Strengths & Weaknesses
Table 111. Hansoh Basic Information, Manufacturing Base and Competitors
Table 112. Hansoh Major Business
Table 113. Hansoh GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 114. Hansoh GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Hansoh Recent Developments/Updates
Table 116. Hansoh Competitive Strengths & Weaknesses
Table 117. Huiren Bio Basic Information, Manufacturing Base and Competitors
Table 118. Huiren Bio Major Business
Table 119. Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product and Services
Table 120. Huiren Bio GLP-1 Combination and Multi-agonist Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Huiren Bio Recent Developments/Updates
Table 122. Huiren Bio Competitive Strengths & Weaknesses
Table 123. Global Key Players of GLP-1 Combination and Multi-agonist Drugs Upstream (Raw Materials)
Table 124. Global GLP-1 Combination and Multi-agonist Drugs Typical Customers
Table 125. GLP-1 Combination and Multi-agonist Drugs Typical Distributors
LIST OF FIGURES
Figure 1. GLP-1 Combination and Multi-agonist Drugs Picture
Figure 2. World GLP-1 Combination and Multi-agonist Drugs Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World GLP-1 Combination and Multi-agonist Drugs Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 5. World GLP-1 Combination and Multi-agonist Drugs Average Price (2021-2032) & (US$/Unit)
Figure 6. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Region (2021-2032)
Figure 7. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Region (2021-2032)
Figure 8. North America GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 9. Europe GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 10. China GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 11. Japan GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 12. India GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 13. GLP-1 Combination and Multi-agonist Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 16. World GLP-1 Combination and Multi-agonist Drugs Consumption Market Share by Region (2021-2032)
Figure 17. United States GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 18. China GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 19. Europe GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 20. Japan GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 21. South Korea GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 22. ASEAN GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 23. India GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of GLP-1 Combination and Multi-agonist Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for GLP-1 Combination and Multi-agonist Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for GLP-1 Combination and Multi-agonist Drugs Markets in 2025
Figure 27. United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share 2025
Figure 31. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share 2025
Figure 32. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share 2025
Figure 33. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Type in 2025
Figure 35. GIP/GLP-1 Dual Agonist
Figure 36. GLP-1/Glucagon Dual Agonist
Figure 37. Amylin/GLP-1 Combination
Figure 38. GIP/GLP-1/Glucagon Tri-agonist
Figure 39. GLP-1 Plus Small Molecule
Figure 40. Other
Figure 41. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Type (2021-2032)
Figure 42. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Type (2021-2032)
Figure 43. World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2032) & (US$/Unit)
Figure 44. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 45. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Indication in 2025
Figure 46. Obesity
Figure 47. Type 2 Diabetes
Figure 48. MASH
Figure 49. Cardiometabolic Disease
Figure 50. Other
Figure 51. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Indication (2021-2032)
Figure 52. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Indication (2021-2032)
Figure 53. World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2021-2032) & (US$/Unit)
Figure 54. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 55. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Dosage Form in 2025
Figure 56. Peptide Injection
Figure 57. Long-acting Injection
Figure 58. Oral Candidate
Figure 59. Combination Kit
Figure 60. Other
Figure 61. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Dosage Form (2021-2032)
Figure 62. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Dosage Form (2021-2032)
Figure 63. World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2021-2032) & (US$/Unit)
Figure 64. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 65. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Application in 2025
Figure 66. Obesity Clinics
Figure 67. Endocrinology Departments
Figure 68. Metabolic Disease Centers
Figure 69. Clinical Trial Sites
Figure 70. Hospital Pharmacies
Figure 71. Retail Pharmacies
Figure 72. Other
Figure 73. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Application (2021-2032)
Figure 74. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Application (2021-2032)
Figure 75. World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2032) & (US$/Unit)
Figure 76. GLP-1 Combination and Multi-agonist Drugs Industry Chain
Figure 77. GLP-1 Combination and Multi-agonist Drugs Procurement Model
Figure 78. GLP-1 Combination and Multi-agonist Drugs Sales Model
Figure 79. GLP-1 Combination and Multi-agonist Drugs Sales Channels, Direct Sales, and Distribution
Figure 80. Methodology
Figure 81. Research Process and Data Source
Figure 1. GLP-1 Combination and Multi-agonist Drugs Picture
Figure 2. World GLP-1 Combination and Multi-agonist Drugs Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World GLP-1 Combination and Multi-agonist Drugs Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 5. World GLP-1 Combination and Multi-agonist Drugs Average Price (2021-2032) & (US$/Unit)
Figure 6. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Region (2021-2032)
Figure 7. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Region (2021-2032)
Figure 8. North America GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 9. Europe GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 10. China GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 11. Japan GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 12. India GLP-1 Combination and Multi-agonist Drugs Production (2021-2032) & (K Units)
Figure 13. GLP-1 Combination and Multi-agonist Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 16. World GLP-1 Combination and Multi-agonist Drugs Consumption Market Share by Region (2021-2032)
Figure 17. United States GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 18. China GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 19. Europe GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 20. Japan GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 21. South Korea GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 22. ASEAN GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 23. India GLP-1 Combination and Multi-agonist Drugs Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of GLP-1 Combination and Multi-agonist Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for GLP-1 Combination and Multi-agonist Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for GLP-1 Combination and Multi-agonist Drugs Markets in 2025
Figure 27. United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: GLP-1 Combination and Multi-agonist Drugs Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: GLP-1 Combination and Multi-agonist Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share 2025
Figure 31. China Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share 2025
Figure 32. Rest of World Based Manufacturers GLP-1 Combination and Multi-agonist Drugs Production Market Share 2025
Figure 33. World GLP-1 Combination and Multi-agonist Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Type in 2025
Figure 35. GIP/GLP-1 Dual Agonist
Figure 36. GLP-1/Glucagon Dual Agonist
Figure 37. Amylin/GLP-1 Combination
Figure 38. GIP/GLP-1/Glucagon Tri-agonist
Figure 39. GLP-1 Plus Small Molecule
Figure 40. Other
Figure 41. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Type (2021-2032)
Figure 42. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Type (2021-2032)
Figure 43. World GLP-1 Combination and Multi-agonist Drugs Average Price by Type (2021-2032) & (US$/Unit)
Figure 44. World GLP-1 Combination and Multi-agonist Drugs Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 45. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Indication in 2025
Figure 46. Obesity
Figure 47. Type 2 Diabetes
Figure 48. MASH
Figure 49. Cardiometabolic Disease
Figure 50. Other
Figure 51. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Indication (2021-2032)
Figure 52. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Indication (2021-2032)
Figure 53. World GLP-1 Combination and Multi-agonist Drugs Average Price by Indication (2021-2032) & (US$/Unit)
Figure 54. World GLP-1 Combination and Multi-agonist Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 55. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Dosage Form in 2025
Figure 56. Peptide Injection
Figure 57. Long-acting Injection
Figure 58. Oral Candidate
Figure 59. Combination Kit
Figure 60. Other
Figure 61. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Dosage Form (2021-2032)
Figure 62. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Dosage Form (2021-2032)
Figure 63. World GLP-1 Combination and Multi-agonist Drugs Average Price by Dosage Form (2021-2032) & (US$/Unit)
Figure 64. World GLP-1 Combination and Multi-agonist Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 65. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Application in 2025
Figure 66. Obesity Clinics
Figure 67. Endocrinology Departments
Figure 68. Metabolic Disease Centers
Figure 69. Clinical Trial Sites
Figure 70. Hospital Pharmacies
Figure 71. Retail Pharmacies
Figure 72. Other
Figure 73. World GLP-1 Combination and Multi-agonist Drugs Production Market Share by Application (2021-2032)
Figure 74. World GLP-1 Combination and Multi-agonist Drugs Production Value Market Share by Application (2021-2032)
Figure 75. World GLP-1 Combination and Multi-agonist Drugs Average Price by Application (2021-2032) & (US$/Unit)
Figure 76. GLP-1 Combination and Multi-agonist Drugs Industry Chain
Figure 77. GLP-1 Combination and Multi-agonist Drugs Procurement Model
Figure 78. GLP-1 Combination and Multi-agonist Drugs Sales Model
Figure 79. GLP-1 Combination and Multi-agonist Drugs Sales Channels, Direct Sales, and Distribution
Figure 80. Methodology
Figure 81. Research Process and Data Source
